HolstJJ. The physiology of glucagon-like peptide 1. Physiol Rev, 2007; 87:1409–1439.
2.
BoseAK, MocanuMM, CarrRDet al.Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes, 2005; 54:146–151.
3.
BoseAK, MocanuMM, CarrRDet al.Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther, 2005; 19:9–11.
4.
BoseAK, MocanuMM, CarrRDet al.Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6k pathway. Cardiovasc Drugs Ther, 2007; 21:253–256.
5.
OssumA, van DeursU, EngstromTet al.The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res, 2009; 60:411–417.
6.
SonneDP, EngstromT, TreimanM. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept, 2008; 146:243–249.
7.
BanK, Noyan-AshrafMH, HoeferJet al.Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008; 117:2340–2350.
HuisamenB, GenadeS, LochnerA. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr, 2008; 19:77–83.
10.
Noyan-AshrafMH, MomenMA, BanKet al.GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 2009; 58:975–983.
11.
DokkenBB, La BonteLR, Davis-GormanGet al.Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res, 2011; 43:300–305.
12.
BanK, KimKH, ChoCKet al.Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology, 2010; 151:1520–1531.
13.
BrownSB, LibonatiJR, SelakMAet al.Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther, 2010; 24:197–205.
14.
BaoW, AravindhanK, AlsaidHet al.Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency. PLoS One, 2011; 6:e23570.
15.
KavianipourM, EhlersMR, MalmbergKet al.Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides, 2003; 24:569–578.
16.
KristensenJ, MortensenUM, SchmidtMet al.Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord, 2009; 9:31.
17.
TimmersL, HenriquesJP, de KleijnDPet al.Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol, 2009; 53:501–510.
18.
LonborgJ, VejlstrupN, KelbaekHet al.Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J, 2012; 33:1491–1499.
19.
YeY, KeyesKT, ZhangCet al.The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol, 2010; 298:H1454–H1465.
20.
KuHC, ChenWP, SuMJ. Dpp4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol, 2011; 384:197–207.
21.
HuisamenB, GenisA, MaraisEet al.Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther, 2011; 25:13–20.
22.
YeY, Perez-PoloJR, AguilarDet al.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol, 2011; 106:925–952.
23.
BirnbaumY, CastilloAC, LingSet al.Amplification of the myocardial infarct size limiting effects of exenatide with cilostazol, a phosphodiesterase III inhibitor [abstract]J Am Col Cardiol, 2012; 59:A110.
24.
BirnbaumY, CastilloAC, QianJet al.Phosphodiesterase III inhibition increases camp levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drug Ther, 2012Aug31[Epub ahead of print].
25.
RavassaS, ZudaireA, DiezJ. GLP-1 and cardioprotection: From bench to bedside. Cardiovasc Res, 2012; 94:316–323.
26.
SanadaS, AsanumaH, TsukamotoOet al.Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation, 2004; 110:51–57.
27.
InserteJ, Garcia-DoradoD, Ruiz-MeanaMet al.Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism. Cardiovasc Res, 2004; 64:105–114.
28.
SanadaS, KitakazeM, PapstPJet al.Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: The role of protein kinase A and p38 mitogen-activated protein kinase. Circulation, 2001; 104:705–710.
29.
VadasO, BurkeJE, ZhangXet al.Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal, 2011; 4.
30.
CosentinoC, Di DomenicoM, PorcelliniAet al.P85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival. Oncogene, 2007; 26:2095–2103.
31.
De GregorioG, CoppaA, CosentinoCet al.The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene, 2007; 26:2039–2047.
32.
BellisA, CastaldoD, TrimarcoVet al.Cross-talk between PKA and AKT protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler Thromb Vasc Biol, 2009; 29:1207–1212.
33.
ManickavasagamS, YeY, LinYet al.The cardioprotective effect of a statin and cilostazol combination: Relationship to AKT and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther, 2007; 21:321–330.
34.
HarrisMB, BlackstoneMA, SoodSGet al.Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol, 2004; 287:H560–H566.
35.
HausenloyDJ, YellonDM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res, 2006; 70:240–253.
36.
ShaywitzAJ, GreenbergME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem, 1999; 68:821–861.
NagyN, ShirotoK, MalikGet al.Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol, 2007; 42:981–990.
39.
DasS, CordisGA, MaulikNet al.Pharmacological preconditioning with resveratrol: Role of CREB-dependent bcl-2 signaling via adenosine a3 receptor activation. Am J Physiol Heart Circ Physiol, 2005; 288:H328–H335.
40.
EliseevRA, VanwinkleB, RosierRNet al.Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB. J Biol Chem, 2004; 279:46748–46754.
41.
MocanuMM, FieldDC, YellonDM. A potential role for PTEN in the diabetic heart. Cardiovasc Drugs Ther, 2006; 20:319–321.
42.
TsangA, HausenloyDJ, MocanuMMet al.Preconditioning the diabetic heart: The importance of AKT phosphorylation. Diabetes, 2005; 54:2360–2364.
43.
BirnbaumY, YeY, LinY, FreebergSY, NishiSP, MartinezJD, HuangMH, UretskyBF, Perez-PoloJR. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation, 2006; 114:929–935.
44.
YeY, LinY, Perez-PoloJRet al.Phosphorylation of 5-lipoxygenase at ser523 by protein kinase a determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol, 2008; 181:3515–3523.
45.
KeyesKT, YeY, LinYet al.Resolvin e1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol, 2010; 299:H153–H164.
